Bone marrow purging, 4-hydroperoxycyclophosphamide, and the FDA.
Rowley
S D
SD
D000208:Acute Disease; D001853:Bone Marrow / Q000473:pathology; D016465:Bone Marrow Purging; D002986:Clinical Trials as Topic / Q000592:standards*; D017321:Clinical Trials, Phase I as Topic / Q000592:standards; D017322:Clinical Trials, Phase II as Topic / Q000379:methods / Q000592:standards; D003520:Cyclophosphamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D004345:Drug Industry; D004363:Drug Utilization; D004992:Ethics, Medical; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology / Q000628:therapy; D015337:Multicenter Studies as Topic; D018365:Neoplasm, Residual; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
C048341:mafosfamide; D003520:Cyclophosphamide; C011272:perfosfamide